Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma

Takeichi Fuku

Division of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan

Search for more papers by this author

Shuho Semba,

Shuho Semba

Division of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan

Search for more papers by this author

Hirokazu Yutori,

Hirokazu Yutori

Division of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan

Search for more papers by this author

Hiroshi Yokozaki,

Hiroshi Yokozaki

Division of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan

Search for more papers by this author

Takeichi Fuku,

Takeichi Fuku

Division of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan

Search for more papers by this author

Shuho Semba,

Shuho Semba

Division of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan

Search for more papers by this author

Hirokazu Yutori,

Hirokazu Yutori

Division of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan

Search for more papers by this author

Hiroshi Yokozaki,

Hiroshi Yokozaki

Division of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan

Search for more papers by this author

First published: 06 August 2007

https://doi.org/10.1111/j.1440-1827.2007.02140.x

Citations: 49

Shuho Semba, MD, PhD, Division of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Email: [email protected]

Share a link

Email
Wechat
Bluesky

Abstract

Phosphorylation of checkpoint kinase 2 (Chk2) at Thr68 (pChk2) induced by DNA double-strand breaks is required for inhibition of cell cycle progression in the G₂ phase. The purpose of the present paper was to investigate the expression of wild-type p53-induced phosphatase 1 (Wip1 or PPM1D), a negative regulator of Chk2, to better understand its role in human gastric cancer. In non-neoplastic gastric mucosa, most epithelial cells exhibited Wip1-positive and pChk2-negative immunoreactivity, whereas an inverse pattern of protein expression was detected at the surface of the foveolar epithelium. In tumor tissues, 74% of 53 gastric cancers had intense Wip1 immunoreactivity and close correlation with both tumor size (P = 0.0497) and Chk2 dephosphorylation (P = 0.0213). In MKN-74 gastric cancer cells, ionizing radiation (IR)-induced Wip1 upregulation was detected at protein levels, but the Chk2-mediated cell cycle regulatory mechanism was disrupted. In addition, protease inhibitor Z-Leu-Leu-Leu (ZLLL) effectively upregulated Wip1 levels in the presence or absence of IR, suggesting that Wip1 expression can be modulated post-transcriptionally. Understanding the Wip1-mediated signaling pathway in gastric cancer may provide useful information for the development of new chemo- and radiotherapies.

REFERENCES

1 Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000; 408: 433–9.
10.1038/35044005
CAS PubMed Web of Science® Google Scholar
2 Goodarzi AA, Jonnalagadda JC, Douglas P et al. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J 2004; 23: 4451–61.
10.1038/sj.emboj.7600455
CAS PubMed Web of Science® Google Scholar
3 Lukas C, Falck J, Bartkova J, Bartek J, Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol 2003; 5: 255–60.
10.1038/ncb945
CAS PubMed Web of Science® Google Scholar
4 Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000; 97: 10 389–94.
10.1073/pnas.190030497
Web of Science® Google Scholar
5 Melchionna R, Chen XB, Blasina A, McGowan CH. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol 2000; 2: 762–5.
10.1038/35036406
CAS PubMed Web of Science® Google Scholar
6 Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421–9.
10.1016/S1535-6108(03)00110-7
CAS PubMed Web of Science® Google Scholar
7 Lee SB, Kim SH, Bell DW et al. Destabilization of CHK2 by a missense mutation associated with Li–Fraumeni syndrome. Cancer Res 2001; 61: 8062–7.
CAS PubMed Web of Science® Google Scholar
8 Craig AL, Hupp TR. The regulation of CHK2 in human cancer. Oncogene 2004; 23: 8411–18.
10.1038/sj.onc.1208035
CAS PubMed Web of Science® Google Scholar
9 Fiscella M, Zhang H, Fan S et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997; 94: 6048–53.
10.1073/pnas.94.12.6048
CAS PubMed Web of Science® Google Scholar
10 Takekawa M, Adachi M, Nakahata A et al. p53-inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000; 19: 6517–26.
10.1093/emboj/19.23.6517
CAS PubMed Web of Science® Google Scholar
11 Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 2005; 19: 1162–74.
10.1101/gad.1291305
CAS PubMed Web of Science® Google Scholar
12 Oliva-Trastoy M, Berthonaud V, Chevalier A et al. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumor suppressor kinase. Oncogene 2007; 26: 1449–58.
10.1038/sj.onc.1209927
CAS PubMed Web of Science® Google Scholar
13 Hirasawa A, Saito-Ohara F, Inoue J et al. Association of 17q21–q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003; 9: 1995–2004.
CAS PubMed Web of Science® Google Scholar
14 Saito-Ohara F, Imoto I, Inoue J et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003; 63: 1876–83.
CAS PubMed Web of Science® Google Scholar
15 Sinclair CS, Rowley M, Naderi A, Couch FJ. The 17q23 amplicon and breast cancer. Breast Cancer Res Treat 2003; 78: 313–22.
10.1023/A:1023081624133
CAS PubMed Web of Science® Google Scholar
16 Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma−2nd English Edition: Response assessment of chemotherapy and radiotherapy for gastric carcinoma: Clinical criteria. Gastric Cancer 2001; 4: 1–8.
10.1007/s101200100009
PubMed Google Scholar
17 Sobin LH, Wittekind CH. UICC TNM Classification of Malignant Tumor, 5th edn. New York: John Wiley and Sons, 1997.
Google Scholar
18 Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643–9.
10.1038/25292
CAS PubMed Web of Science® Google Scholar
19 Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907–13.
10.1038/nature03485
CAS PubMed Web of Science® Google Scholar
20 Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12: 440–50.
10.1016/j.molmed.2006.07.007
CAS PubMed Web of Science® Google Scholar
21 Haruki N, Saito H, Tatematsu Y et al. Histological type-specific, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 2000; 60: 4689–92.
CAS PubMed Web of Science® Google Scholar
22 The CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100dleC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55–9.
CAS PubMed Web of Science® Google Scholar
23 Wu X, Dong X, Liu W, Chen J. Characterization of CHEK2 mutations in prostate cancer. Hum Mutat 2006; 27: 742–7.
10.1002/humu.20321
CAS PubMed Web of Science® Google Scholar
24 Bulavin DV, Demidov ON, Saito S et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31: 210–15.
10.1038/ng894
CAS PubMed Web of Science® Google Scholar
25 Nannenga B, Lu X, Dumble M et al. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog 2006; 45: 594–604.
10.1002/mc.20195
CAS PubMed Web of Science® Google Scholar
26 Shreeram S, Demidov ON, Hee WK et al. Wip1 phosphatase modulates ATM-dependent signaling pathway. Mol Cell 2006; 23: 757–64.
10.1016/j.molcel.2006.07.010
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume57, Issue9

September 2007

Pages 566-571

Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma

Abstract

REFERENCES

Citing Literature

References

Related

Information